Events & Webinars
Podcasts
Resources
Learning Zone
Products
Service Optimisation & Formularies
Risk Minimisation Materials
Cardiovascular
Women's Health
Nephrology
Oncology
Ophthalmology
Respiratory
Bayer for Professionals
Your Resource Portal
Prostate Cancer Webinars | PP-PF-ONC-GB-0413, February 2024
Oncology
P3 Prostate Cancer Forum: 2024
perspectives, possibilities, progress
PP-NUB-GB-2012, January 2025
ASCO-GU 2023: The DEAR study in nmCRPC
NUBEQA® (darolutamide)
NUBEQA Prescribing Information
PP-NUB-GB-2022, January 2025
ESMO 2024 Shorts Series
NUBEQA® (darolutamide)
NUBEQA Prescribing Information
PP-NUB-GB-2082, January 2025
BNMS 2024
Xofigo®▼ (radium-223 dichloride) | NUBEQA® (darolutamide)
Xofigo Prescribing Information
NUBEQA Prescribing Information
PP-XOF-GB-0598, January 2025
Evolving mCRPC treatment landscape in 2023
Xofigo®▼ (radium-223 dichloride)
Xofigo Prescribing Information
PP-XOF-GB-0505, February2024
BAUS 2024: Management of CV toxicity and bone health
NUBEQA® (darolutamide)
NUBEQA Prescribing Information
PP-NUB-GB-2079, January 2025
BAUS 2024: Imaging and nmCRPC
NUBEQA® (darolutamide)
NUBEQA Prescribing Information
PP-NUB-GB-2081, January 2025
BAUS 2024: Urology and Oncology in Partnership
NUBEQA® (darolutamide)
NUBEQA Prescribing Information
PP-NUB-GB-2080, January 2025
Treatment tolerability in mHSPC and nmCRPC
NUBEQA® (darolutamide)
NUBEQA Prescribing Information
PP-NUB-GB-2036, January 2025
